Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 10/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.34 |
| ▸ | GRM4 | Q14833 | 2/20 | 0.34 |
| ▸ | CYP2B6 | P20813 | 1/20 | 0.33 |
| ▸ | TENT4A | Q5XG87 | 1/20 | 0.33 |
| ▸ | TENT4B | Q8NDF8 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29157688 | 0.84 | BRD4 (0.37) | KDM4EALDH1A1L3MBTL1HTTHPGD | |
| SCHEMBL30843850 | 0.84 | BRD4 (0.37) | KDM4EALDH1A1L3MBTL1HTTHPGD | |
| SCHEMBL26967916 | 0.75 | NPSR1 (0.40) | KDM4EALDH1A1HTTHPGDKMT2A | |
| SCHEMBL26967891 | 0.74 | PDPK1 (0.36) | L3MBTL1TSHR | |
| SCHEMBL27200088 | 0.70 | CYP2B6 (0.36) | KDM4EALDH1A1L3MBTL1HPGDKMT2A | |
| SCHEMBL21327178 | 0.69 | CYP2B6 (0.38) | KDM4EALDH1A1KMT2AUSP2CYP2B6 | |
| SCHEMBL31554523 | 0.68 | AAK1 (0.40) | KDM4EALDH1A1 | |
| SCHEMBL21327297 | 0.68 | CYP2B6 (0.35) | KDM4EKMT2AUSP2CYP2B6TENT4A | |
| SCHEMBL28090675 | 0.68 | HTT (0.52) | KDM4EALDH1A1L3MBTL1HTTHPGD | |
| SCHEMBL26617375 | 0.68 | GRM4 (0.49) | KDM4EALDH1A1HTTHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | EXELIXIS, INC. | 2024-05-16 | — | — | US | disclosed |
| EP-4294804-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | Exelixis, Inc. (US) | 2023-12-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240158393-A1 | PYRIDONE COMPOUNDS AND METHODS OF USE | PDXK, PLK2, MAP4K2 | KDM4E 2816/4885ALDH1A1 4282/4885L3MBTL1 3161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.